BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15806458)

  • 1. Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft.
    Tang S; Lai KN
    Am J Kidney Dis; 2005 Apr; 45(4):A55, e61-2. PubMed ID: 15806458
    [No Abstract]   [Full Text] [Related]  

  • 2. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
    Munoz MA; Andrés A; Gallego R; Morales E; Morales JM; Aguado JM; Lumbreras C; Torres A; Rodicio JL; Praga M
    Transplant Proc; 2002 Feb; 34(1):97. PubMed ID: 11959202
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
    Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplantation lymphoproliferative disorder of the T-cell/B-cell type: an unusual manifestation in a renal allograft.
    Wirnsberger GH; Ratschek M; Dimai HP; Holzer H; Mandal AK
    Oncol Rep; 1999; 6(1):29-32. PubMed ID: 9864396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract]   [Full Text] [Related]  

  • 9. [Virus, immunosuppression, and the kidney transplant recipient].
    Alberú J; Villasís A
    Rev Invest Clin; 2005; 57(4):582-95. PubMed ID: 16315643
    [No Abstract]   [Full Text] [Related]  

  • 10. Indications for mycofenolate mofetil therapy after liver transplantation.
    Platz KP; Mueller AR; Neuhaus P
    Transplant Proc; 1997 Nov; 29(7):2880-1. PubMed ID: 9365601
    [No Abstract]   [Full Text] [Related]  

  • 11. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful therapy of chronic renal allograft failure by enhanced immunosuppression.
    Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R
    Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
    Ninan MJ; Datta YH
    Am J Hematol; 2010 Aug; 85(8):635-7. PubMed ID: 20578201
    [No Abstract]   [Full Text] [Related]  

  • 16. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant tumours following immunosuppression in renal transplantation.
    Birkeland SA; Kemp E
    Proc Eur Dial Transplant Assoc; 1973; 10(0):429-33. PubMed ID: 4370181
    [No Abstract]   [Full Text] [Related]  

  • 18. MMF-based regimen in maintenance therapy after kidney transplantation.
    Wu MJ; Shu KH; Cheng CH; Chen CH; Lian JD
    Transplant Proc; 2000 Nov; 32(7):1748-50. PubMed ID: 11119918
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.
    Kontny U; Boppana S; Jung A; Goebel H; Strahm B; Peters A; Dormann S; Werner M; Bader P; Fisch P; Niemeyer C
    Haematologica; 2005 Nov; 90 Suppl():ECR27. PubMed ID: 16266918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.